- Home
- LIXT vs CMBM Comparison
LIXT vs CMBM Comparison
Compare LIXT & CMBM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIXT
- CMBM
- Stock Information
- Founded
- LIXT 2005
- CMBM 2011
- Country
- LIXT United States
- CMBM United States
- Employees
- LIXT N/A
- CMBM N/A
- Industry
- LIXT Biotechnology: Pharmaceutical Preparations
- CMBM Radio And Television Broadcasting And Communications Equipment
- Sector
- LIXT Health Care
- CMBM Technology
- Exchange
- LIXT Nasdaq
- CMBM Nasdaq
- Market Cap
- LIXT 24.4M
- CMBM 25.0M
- IPO Year
- LIXT N/A
- CMBM 2019
- Fundamental
- Price
- LIXT $4.81
- CMBM $0.90
- Analyst Decision
- LIXT
- CMBM Buy
- Analyst Count
- LIXT 0
- CMBM 1
- Target Price
- LIXT N/A
- CMBM $3.00
- AVG Volume (30 Days)
- LIXT 155.1K
- CMBM 259.1K
- Earning Date
- LIXT 11-11-2025
- CMBM 11-06-2025
- Dividend Yield
- LIXT N/A
- CMBM N/A
- EPS Growth
- LIXT N/A
- CMBM N/A
- EPS
- LIXT N/A
- CMBM N/A
- Revenue
- LIXT N/A
- CMBM $172,215,000.00
- Revenue This Year
- LIXT N/A
- CMBM N/A
- Revenue Next Year
- LIXT N/A
- CMBM $17.73
- P/E Ratio
- LIXT N/A
- CMBM N/A
- Revenue Growth
- LIXT N/A
- CMBM N/A
- 52 Week Low
- LIXT $0.64
- CMBM $0.23
- 52 Week High
- LIXT $6.26
- CMBM $1.69
- Technical
- Relative Strength Index (RSI)
- LIXT 51.75
- CMBM 53.32
- Support Level
- LIXT $4.77
- CMBM $0.83
- Resistance Level
- LIXT $5.53
- CMBM $0.96
- Average True Range (ATR)
- LIXT 0.47
- CMBM 0.10
- MACD
- LIXT -0.08
- CMBM -0.01
- Stochastic Oscillator
- LIXT 21.66
- CMBM 32.09
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.
About CMBM Cambium Networks Corporation
Cambium Networks Corp provides wireless broadband networking infrastructure solutions for network operators, including medium-sized wireless Internet service providers, enterprises, and government agencies. The company geographically operates in North America; Europe, Middle East and Africa; Caribbean and Latin America; and Asia Pacific. It derives maximum revenue from North America.